Oxford COVID vaccine promising in elderly

Laverne Higgins
November 19, 2020

Researchers analysed the results of the phase II of clinical trials, which were conducted on 560 healthy adults.

"The reason that we're so delighted is the we're seeing the immune responses look exactly the same, even in those who are over 70 years of age", Pollard said.

Immunogenicity was similar across age groups after a boost vaccination.

The prestigious scientific journal said the findings were "encouraging" because older individuals are at disproportionate risk of severe COVID-19.

Dr. Andrew Pollard says scientists expect to report results from the late-stage trials of their COVID-19 vaccine by Christmas. Earlier, another United States pharma company, Moderna Inc, had claimed its vaccine was 94.5 percent effective against COVID-19.

'We were pleased to see that our vaccine was not only well tolerated in older adults; it also stimulated similar immune responses to those seen in younger volunteers.

Bahrain, Israel agree to set up embassies in Jerusalem meet
For years, Gulf states' relations with Israel have improved due to their shared concerns about Iranian policies in the region. Trump's outgoing administration has made isolating arch foe Iran a centrepiece of its regional policy.

The data were based on earlier, Phase Two human trials of the vaccine.

"The next step", he said, "will be to see if this translates into protection from the disease itself".

The University which is developing its vaccine in collaboration with AstraZeneca Plc said that it will release its findings from the final phase in the coming weeks, a report by Bloomberg said on Thursday.

"We hope this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure".

"As of Oct 26, 2020, 13 serious adverse events occurred during the study period, none of which were considered to be related to either study vaccine". Unlike the Pfizer and Moderna programs, which rely on a new vaccine technology called messenger RNA, the vaccine developed by AstraZeneca and Oxford represents a more traditional approach.

The Oxford vaccine spurred trial participants' immune systems to find and attack cells infected with the virus, and following a second, booster shot was effective in attacking the virus in the bloodstream, according to the interim results. The data is "another brick in the house that we're trying to build for this vaccine".

Other reports by

Discuss This Article